<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rentrad</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник рентгенологии и радиологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of radiology and nuclear medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0042-4676</issn><issn pub-type="epub">2619-0478</issn><publisher><publisher-name>Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20862/0042-4676-2025-106-6-207-217</article-id><article-id custom-type="elpub" pub-id-type="custom">rentrad-1010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Комплексная мультимодальная лучевая диагностика нейрофиброматозов</article-title><trans-title-group xml:lang="en"><trans-title>Comprehensive Multi-Modal Radiological Diagnostics of Neurofibromatosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3261-9986</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Malov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Малов Алексей Анатольевич, ассистент кафедры онкологии с курсом лучевой диагностики и лучевой терапии, врач-рентгенолог отделения лучевой диагностики № 2, преподаватель кафедры радиологии, радиотерапии, радиационной гигиены и радиационной безопасности им. академиков А.С. Павлова и Ф.Г. Кроткова</p><p>ул. Бутлерова, 49, Казань, 420012</p><p>ул. Оренбургский тракт, 140, Казань, 420011</p><p>ул. Баррикадная, 2/1, стр. 1, Москва, 123001</p></bio><bio xml:lang="en"><p>Aleksei A. Malov, Assistant Professor, Chair of Oncology with a Course in Radiation Diagnostics and Radiation Therapy; Radiologist, Department of Radiology Diagnostics No. 2; Lecturer, Chair of Radiology, Radiotherapy, Radiation Hygiene and Radiation Safety</p><p>ul. Butlerova, 49, Kazan, 420012</p><p>ul. Orenburgsky trakt, 140, Kazan, 420011</p><p>ul. Barrikadnaya, 2/1, str. 1, Moscow, 123001</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-7183-2500</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макарова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Makarova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Макарова Алина Сергеевна, ординатор</p><p>ул. Бутлерова, 49, Казань, 420012</p></bio><bio xml:lang="en"><p>Alina S. Makarova, Resident</p><p>ul. Butlerova, 49, Kazan, 420012</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-8504-5760</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Портнова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Portnova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Портнова Екатерина Александровна, ординатор</p><p>ул. Бутлерова, 49, Казань, 420012</p></bio><bio xml:lang="en"><p>Ekaterina A. Portnova, Resident</p><p>ul. Butlerova, 49, Kazan, 420012</p></bio><email xlink:type="simple">katya.portnova1999@list.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России;&#13;
ГАУЗ «Детская республиканская клиническая больница Министерства здравоохранения Республики Татарстан»;&#13;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University;&#13;
Children’s Republican Clinical Hospital;&#13;
Russian Medical Academy of Continuing Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>03</month><year>2026</year></pub-date><volume>106</volume><issue>6</issue><fpage>207</fpage><lpage>217</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Малов А.А., Макарова А.С., Портнова Е.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Малов А.А., Макарова А.С., Портнова Е.А.</copyright-holder><copyright-holder xml:lang="en">Malov A.A., Makarova A.S., Portnova E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.russianradiology.ru/jour/article/view/1010">https://www.russianradiology.ru/jour/article/view/1010</self-uri><abstract><p>Цель: анализ возможностей и изучение информативности компьютерной томографии (КТ) и магнитно-резонансной томографии (МРТ) в визуализации клинических проявлений нейрофиброматоза.Материал и методы. На основе ретроспективного анализа историй болезней сформирована группа пациентов с нейрофиброматозами 1-го и 2-го типов, наблюдающихся в ГАУЗ «Детская республиканская клиническая больница Министерства здравоохранения Республики Татарстан». Обследовано 35 детей с подтвержденным или клинически предполагаемым заболеванием группы факоматозов. Пациенты соответствовали следующим критериям включения: возраст от 0 до 18 лет включительно, мультисистемные проявления по данным КТ и МРТ, характерные визуальные изменения.Результаты. При исследовании головного и спинного мозга определены фокальные зоны повышенной интенсивности сигнала (77,14%), глиомы зрительных нервов с распространением на хиазму (25,00%), периферические нейрофибромы (34,29%). Поражения органов грудной клетки включали: плексиформ­ ные нейрофибромы паравазально в области средостения и паравертебрально (5,71%), периферические нейрофибромы (2,86%). Исследование органов брюшной полости и забрюшинного пространства выявило: периферические нейрофибромы (2,86%), многоузловое объемное образование (2,86%). При исследовании нижних конечностей обнаружены следующие патологии: плексиформные нейрофибромы с поражением мягких тканей конечности (5,71%), фиброзные дисплазии (5,71%). МРТ продемонстрировала более высокую чувствительность в оценке поражения центральной нервной системы ввиду высокой тканевой контрастности, позволяющей детально оценить размер, локализацию и характер роста опухолей нервной ткани, а также ее взаимоотношения с окружающими нервными структурами. КТ предпочтительна для оценки висцеральных структур брюшной полости и забрюшинного пространства, выявления поражения костей, органов грудной клетки, опосредованных нейрофиброматозом.Заключение. Мультимодальный подход, интегрирующий применение КТ и МРТ, обеспечивает комплексное визуальное представление о проявлениях нейрофиброматоза.</p></abstract><trans-abstract xml:lang="en"><p>Objective: to analyze the possibilities and study the informative value of computed tomography (CT) and magnetic resonance imaging (MRI) in visualizing the clinical manifestations of neurofibromatosis.Material and methods. Based on retrospective analysis of the medical records, a group of types 1 and 2 neurofibromatose patients observed at the Children’s Republican Clinical Hospital was formed. In total, 35 children with a confirmed or clinically suspected disease of phacomatoses group were examined. The patients met the following inclusion criteria: age from 0 to 18 years inclusive, СT and MRI multi-system manifestations, characteristic visual changes.Results. Brain and spinal cord study revealed focal areas of signal intensity (77.14%), optic nerve gliomas with a spread to chiasm (25,00%), peripheral neurofibromas (34.29%). Chest lesions included plexiform neurofibromas paravasally in the mediastinum and paravertebrally (5.71%), peripheral neurofibromas (2.86%). Examination of the abdominal cavity and retroperitoneal space showed peripheral neurofibromas (2.86%), and multi-node volumetric masses (2.86%). In the lower limbs, the following lesions were found: plexiform neurofibromas with limb soft tissue lesions (5.71%), fibrous dysplasia (5.71%). MRI showed a higher sensitivity in assessing central nervous system damage due to the high tissue contrast, which makes it possible to assess in detail the size, localization and growth pattern of the nervous tissue tumors, as well as their relation to the surrounding nervous structures. CT is preferable for evaluating visceral structures of the abdominal cavity and retroperitoneal space, detecting bone and thoracic lesions mediated by neurofibromatosis.Conclusion. A multi-modal approach integrating the use of CT and MRI provides a comprehensive visual representation of neurofibromatosis manifestations.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нейрофиброматоз</kwd><kwd>компьютерная томография</kwd><kwd>магнитно-резонансная томография.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>neurofibromatosis</kwd><kwd>computed tomography</kwd><kwd>magnetic resonance imaging.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Юсупова Л.А., Юнусова Е.И., Гараева З.Ш., Мавлютова Г.И. Факоматозы: диагностика, клиника и особенности течения различных форм заболевания. Лечащий врач. 2018; 5: 35–40.</mixed-citation><mixed-citation xml:lang="en">Yusupova LA, Yunusova EI, Garayeva ZSh, Mavlyutova GI. Phacomatosis: diagnosis, clinical features and peculiarities of different forms of the disease. Lechaschi vrach. 2018; 5: 35–40 (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Старосельцева О.А., Нуднов Н.В., Радутная М.Л. и др. Нейрофиброматоз II типа с вовлечением головного и спинного мозга. Вестник рентгенологии и радиологии. 2021; 102(2): 98–108. https://doi.org/10.20862/0042-4676-2021-102-2-98-108.</mixed-citation><mixed-citation xml:lang="en">Staroseltseva OA, Nudnov NV, Radutnaya ML, et al. Neurofibromatosis type 2 involving the brain and spinal cord. Journal of Radiology and Nuclear Medicine. 2021; 102(2): 98–108 (in Russ). https://doi.org/10.20862/0042-4676-2021-102-2-98-108.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ghalavand MA, Asghari A, Farhadi M, et al. The genetic landscape and possible therapeutics of neurofibromatosis type 2. Cancer Cell Int. 2023; 23(1): 99. https://doi.org/10.1186/s12935-023-02940-8.</mixed-citation><mixed-citation xml:lang="en">Ghalavand MA, Asghari A, Farhadi M, et al. The genetic landscape and possible therapeutics of neurofibromatosis type 2. Cancer Cell Int. 2023; 23(1): 99. https://doi.org/10.1186/s12935-023-02940-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kallionpää RA, Uusitalo E, Leppävirta J, et al. Prevalence of neurofibromatosis type 1 in the Finnish population. Genet Med. 2018; 20(9): 1082–6. https://doi.org/10.1038/gim.2017.215.</mixed-citation><mixed-citation xml:lang="en">Kallionpää RA, Uusitalo E, Leppävirta J, et al. Prevalence of neurofibromatosis type 1 in the Finnish population. Genet Med. 2018; 20(9): 1082–6. https://doi.org/10.1038/gim.2017.215.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Uusitalo E, Rantanen M, Kallionpää RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016; 34(17): 1978–86. https://doi.org/10.1200/JCO.2015.65.3576.</mixed-citation><mixed-citation xml:lang="en">Uusitalo E, Rantanen M, Kallionpää RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016; 34(17): 1978–86. https://doi.org/10.1200/JCO.2015.65.3576.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Menor F, Marti-Bonmati L, Arana E, et al. Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur J Radiol. 1998; 26(2): 121–31. https://doi.org/10.1016/s0720-048x(97)00088-0.</mixed-citation><mixed-citation xml:lang="en">Menor F, Marti-Bonmati L, Arana E, et al. Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur J Radiol. 1998; 26(2): 121–31. https://doi.org/10.1016/s0720-048x(97)00088-0.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tiwari R, Singh AK. Neurofibromatosis type 2. In: Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available at: https://pubmed.ncbi.nlm.nih.gov/29261934 (accessed 03.09.2025).</mixed-citation><mixed-citation xml:lang="en">Tiwari R, Singh AK. Neurofibromatosis type 2. In: Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available at: https://pubmed.ncbi.nlm.nih.gov/29261934 (accessed 03.09.2025).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sur ML, Armat I, Sur G, et al. Neurofibromatosis in children: actually and perspectives. Children. 2022; 9(1): 40. https://doi.org/10.3390/children9010040.</mixed-citation><mixed-citation xml:lang="en">Sur ML, Armat I, Sur G, et al. Neurofibromatosis in children: actually and perspectives. Children. 2022; 9(1): 40. https://doi.org/10.3390/children9010040.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Le C, Thomas A, Lui F. Neurofibromatosis. In: Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459329 (accessed 03.09.2025).</mixed-citation><mixed-citation xml:lang="en">Le C, Thomas A, Lui F. Neurofibromatosis. In: Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459329 (accessed 03.09.2025).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci. 2021; 22(11): 5850. https://doi.org/10.3390/ijms22115850.</mixed-citation><mixed-citation xml:lang="en">Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci. 2021; 22(11): 5850. https://doi.org/10.3390/ijms22115850.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Arenas-Jiménez JJ, Bernabé García JM, Fernández Suárez G, Calvo Blanco J. Optimising the use of iodinated contrast agents in CT scans: vascular, visceral, multiphasic and split-bolus examinations. Radiologia. 2024; 66(Suppl 2): S15–28. https://doi.org/10.1016/j.rxeng.2024.10.001.</mixed-citation><mixed-citation xml:lang="en">Arenas-Jiménez JJ, Bernabé García JM, Fernández Suárez G, Calvo Blanco J. Optimising the use of iodinated contrast agents in CT scans: vascular, visceral, multiphasic and split-bolus examinations. Radiologia. 2024; 66(Suppl 2): S15–28. https://doi.org/10.1016/j.rxeng.2024.10.001.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Кармазановский Г.Г. Спиральная компьютерная томография: болюсное контрастное усиление. М.: ВидарМ; 2005: 376 с.</mixed-citation><mixed-citation xml:lang="en">Karmazanovsky GG. Spiral computed tomography: bolus contrast enhancement. Мoscow: VidarM; 2005: 376 pp (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов В.В., Саввова М.В., Смирнов В.В. Магнитно-резонансная томография в диагностике заболеваний суставов. Обнинск: Артифекс; 2022: 170 с.</mixed-citation><mixed-citation xml:lang="en">Smirnov VV, Savvova MV, Smirnov VV. Magnetic resonance imaging in the diagnosis of joint diseases. Obninsk: Artifeks; 2022: 170 pp (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Petrak B, Lisy J, Kraus J. Focal areas of high-signalintensity on brain T2-weighted magnetic resonance imaging scans are significant for the diagnosis of neurofibromatosis von Recklinghausen type 1. Pediatrics. 2008; 121(2): 147. https://doi.org/10.1542/peds.2007-2022cccccc.</mixed-citation><mixed-citation xml:lang="en">Petrak B, Lisy J, Kraus J. Focal areas of high-signalintensity on brain T2-weighted magnetic resonance imaging scans are significant for the diagnosis of neurofibromatosis von Recklinghausen type 1. Pediatrics. 2008; 121(2): 147. https://doi.org/10.1542/peds.2007-2022cccccc.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Никольский Ю.Е., Чехонацкая М.Л., Приезжева В.Н. и др. Возможности компьютерной и магнитно-резонансной томографии в диагностике неврином черепных нервов (обзор). Саратовский научно-медицинский журнал. 2012; 8(2): 499 – 501.</mixed-citation><mixed-citation xml:lang="en">Nikolskiy YuE, Chekhonatskaya ML, Priezshzeva VN, et al. Features of computed tomography and magnetic resonance imaging in the diagnosis of cranial nerve neurinoma (review). Saratov Journal of Medical Scientific Research. 2012; 8(2): 499 – 501 (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Труфанов Г.Е. (ред.) Лучевая диагностика. М.: ГЭОТАР-Медиа; 2023: 484 с.</mixed-citation><mixed-citation xml:lang="en">Trufanov GE (Ed). Radiation diagnostics. Мoscow: GEOTARMedia; 2023: 484 pp (in Russ).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
